Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finerenone - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Finerenone - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-94-8862; Firialta; Firialta™; KERENDIA; Kerendia

Latest Information Update: 11 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Amides; Antihyperglycaemics; Heart failure therapies; Naphthyridines; Nitriles; Small molecules; Urologics
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Heart failure
  • Preregistration Renal failure
  • Phase III Chronic heart failure; Type 1 diabetes mellitus

Most Recent Events

  • 30 Jul 2026 Preregistration for Renal failure (Adjunctive treatment) in China (PO)
  • 05 Jun 2026 Updated adverse events and efficacy data from the phase-III FIND-CKD trial in Renal-failure released by Bayer HealthCare Pharmaceuticals
  • 01 Jun 2026 Phase-III clinical trials in Heart failure (In children, In infants, In neonates, In adolescents, Combination therapy) in Taiwan (PO) (NCT07192952)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top